bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
2.120
+1.050 (98.13%)
At close: Mar 13, 2026, 4:00 PM EDT
1.951
-0.169 (-7.96%)
After-hours: Mar 13, 2026, 7:59 PM EDT
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.45M in the quarter ending September 30, 2025, a decrease of -38.48%. This brings the company's revenue in the last twelve months to $6.78M, down -27.66% year-over-year. In the year 2024, bioAffinity Technologies had annual revenue of $9.36M with 269.68% growth.
Revenue (ttm)
$6.78M
Revenue Growth
-27.66%
P/S Ratio
1.55
Revenue / Employee
$108,105
Employees
57
Market Cap
9.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inotiv | 514.03M |
| MDxHealth | 107.88M |
| FONAR | 106.03M |
| Exagen | 66.58M |
| XWELL | 29.52M |
| Precipio | 22.80M |
| Insight Molecular Diagnostics | 4.40M |
| iSpecimen | 3.35M |
BIAF News
- 1 day ago - bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga
- 1 day ago - bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - Business Wire
- 4 days ago - bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic - Business Wire
- 11 days ago - bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients - Business Wire
- 17 days ago - bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test - Business Wire
- 23 days ago - New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer - Business Wire
- 25 days ago - Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study - Business Wire
- 4 weeks ago - bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board - Business Wire